Atrial Fibrillation  /  Innovative Medical Research

Every year around 75,000 Americans learn that they have atrial fibrillation (AFib)—the most common type of arrhythmia, or abnormal heart rhythm. Having AFib puts people at an increased risk for stroke, which can be both deadly and costly. Medicare alone is estimated to pay .7 billion per year to treat newly diagnosed atrial fibrillation patients.

18 Matching Facts

Search matching Facts:
No results to display
    • Stroke prevention through optimal anticoagulation
      If half of atrial fibrillation patients who currently receive warfarin in a routine care setting had their anti-coagulation optimized, around 9,000 strokes and more than 29,000 bleeds would be prevented.  
    • Effect of optimal anticoagulation
      If 50% of atrial fibrillation patients who currently receive warfarin in routine medical care were optimally anticoagulated, 9,852 emboli would be prevented and $1.3 billion would be saved each year.  
    • Effects of optimal anticoagulation among AFib patients
      If 50% of individuals with atrial fibrillation who do not receive prophylaxis were optimally anti-coagulated, 19,380 emboli would be prevented and $1.1 billion would be saved each year.  
    • Cost-savings associated with optimal anticoagulation in AFib patients
      If half of all atrial fibrillation patients receiving suboptimal or no anticoagulation instead received optimal anticoagulation, 28,000 strokes could be prevented each year at a savings of around $2.5 billion in direct…  
    • t-PA cost savings
      The total annual benefit to society from t-PA use in the United States is around $363 million—$60 million in direct cost savings to society plus an additional 7,510 QALYs. This means…  
    • Per-patient annual cost of treating stroke in atrial fibrillation patients
      The per-patient annual cost of treating stroke in atrial fibrillation patients was found to be $1,485 in a wellcontrolled anti-coagulation clinic, $3,710 for those receiving warfarin in routine medical care,…  
    • Cost of warfarin therapy for AFib patients
      In patients with nonvalvular atrial fibrillation (AF) and one additional stroke risk factor, warfarin therapy cost $8,000 per quality-adjusted life-year (QALY) saved.  
    • Cost-savings associated with Warfarin use in AFib patients
      Warfarin use in Medicare patients with nonvalvular atrial fibrillation was independently associated with lower medical costs averaging $9,836 per patient, per year.  
    • AFib practice guidelines reduce direct health care costs
      The use of practice guidelines in atrial fibrillation (AF) patients significantly decreased hospitalization and resource utilization—with an average decrease in 30-day total direct health care costs of around $1,400 per patient.  
    • Identifying individuals at high risk for developing AFib
      Using simple bedside measures, identification of individuals at risk for developing atrial fibrillation is feasible. Selecting high-risk individuals for inclusion in atrial fibrillation prevention trials may also enhance prevention strategies.  
    • Catheter ablation reduces risk of stroke and death among AFib patients
      Atrial fibrillation patients who underwent catheter ablation had a reduced risk of stroke and death—2.2% of those who had ablation experienced stroke versus 4.7% on medications alone, and 6% died from…  
    • Decrease in AFib hospitalization rates
      The use of practice guidelines in atrial fibrillation patients saw a decrease in rate of hospitalization from 74%to 38%.  
    • Stroke risk reduction from thrombin inhibitor in AFib patients
      A recently approved direct thrombin inhibitor was found to reduce the risk of stroke/peripheral embolic events in atrial fibrillation patients by 34%, and the risk of hemorrhagic stroke by 74%—compared…  
    • Adjusted-dose warfarin reduced stroke risk in AFib patients
      Meta-analysis of randomized trials found that adjusted-dose warfarin reduced stroke risk in atrial fibrillation patients by 60%. Antiplatelet agents reduced risk by 20%.  
    • Aspirin use in AFib patients
      Meta-analysis of a number of randomized controlled trials found that aspirin use in atrial fibrillation patients reduced stroke risk by an average 22%.  
    • Stroke rates among Afib patients
      In one year, 58,283 of the 1.265 million Medicare beneficiaries with atrial fibrillation that did not receive prophylaxis suffered a stroke. For those who did receive anti-coagulants, 38,468 suffered strokes.  
    • Atrial fibrillation ablation prevents recurrence of AFib
      Atrial fibrillation ablation, which involves using a catheter inserted into the heart to destroy electrical conduction tissue in or near the atria, prevents the recurrence of atrial fibrillation in up…  
    • Effectiveness of pacemaker/defibrillators to control AFib
      Widespread use of pacemaker/defibrillators to control atrial fibrillation could result in a 50% decrease in stroke.